---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-137228"
form_type: "8-K"
ticker: "INO"
cik: "0001055726"
company_name: "INOVIO PHARMACEUTICALS, INC."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T01:50:06.548182+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Inovio Q1 net loss narrows to $30.5M; BLA for INO-3107 on track for H2 2024

## Summary
- BLA submission for INO-3107 (recurrent respiratory papillomatosis) on track for H2 2024 under accelerated approval pathway.
- Phase 3 trial of INO-3112 + LOQTORZI for HPV-related throat cancer advancing; FDA feedback received.
- Net loss $30.5M ($1.31/sh) vs $40.6M ($1.89/sh) in Q1 2023; R&D expenses fell to $20.9M.
- Cash & equivalents $105.6M at Mar 31, 2024; April offering raised net ~$33.2M; cash runway into Q3 2025.

## SEC filing metadata
- accession: 0001193125-24-137228
- form_type: 8-K
- ticker: INO
- cik: 0001055726
- company_name: INOVIO PHARMACEUTICALS, INC.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1055726/000119312524137228/0001193125-24-137228-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1055726/000119312524137228/d774987d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-137228
- JSON: https://secwatch.observer/filing/0001193125-24-137228.json
- Plain text: https://secwatch.observer/filing/0001193125-24-137228.txt

## Key facts
- Earnings Releases
  INOVIO PHARMACEUTICALS, INC. reported financial results for first quarter of 2024.
  - Period: first quarter of 2024
  - Result: reported results
  source text: On May 13, 2024, Inovio Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1055726/000119312524137228/0001193125-24-137228-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.